Home

OS Therapies Incorporated Common Stock (OSTX)

1.7100
-0.0900 (-5.00%)
NYSE · Last Trade: Nov 17th, 5:42 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1.800
Open1.650
Bid1.710
Ask1.750
Day's Range1.620 - 1.820
52 Week Range1.120 - 7.000
Volume355,577
Market Cap10.00M
PE Ratio (TTM)-2.085
EPS (TTM)-0.8
Dividend & YieldN/A (N/A)
1 Month Average Volume321,887

Chart

News & Press Releases

OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
Type C Meeting with US FDA set for December 11, 2025 to address key items following August 27, 2025 End...
Via Newsfile · November 17, 2025
Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · November 17, 2025
OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...
Via Newsfile · October 22, 2025
Earnings Outlook For OS Therapiesbenzinga.com
Via Benzinga · August 18, 2025
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Final FDA Type C Meeting December 11, 2025 - biomarker data to be availableOctober 10, 2025 FDA/Osteosarcoma Institute Workshop narrows...
Via Newsfile · October 17, 2025
OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidatebenzinga.com
OS Therapies reports 75% two-year survival in osteosarcoma trial, plans regulatory filings with the FDA, EMA, and MHRA following positive Phase 2b results.
Via Benzinga · October 10, 2025
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001)100%...
Via Newsfile · October 10, 2025
OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting
Overall survival recognized as key efficacy endpoint in osteosarcoma, where no standard of care existsRapporteur highlights potential broader benefits of...
Via Newsfile · October 9, 2025
OS Therapies to Participate in Fall 2025 Conferences and Events
Daytime Emmy Awards participation - 2 nomination for 'Shelter Me: Cancer Pioneers' Comparative Oncology documentary that features clinicians, veterinarians and...
Via Newsfile · October 7, 2025
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update
Company updates sequence of OST-HER2 regulatory submissions, prioritizing UK MHRA conditional Marketing Authorisation Application (MAA) submission following positive August 2025...
Via Newsfile · September 30, 2025
OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
New York, New York--(Newsfile Corp. - September 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...
Via Newsfile · September 19, 2025
OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit
Clinical data from Phase 1b prostate cancer trial to be released in Q4/25Additionally, updated 2-year overall survival data from all...
Via Newsfile · September 12, 2025
Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)
Dallas, Texas--(Newsfile Corp. - September 8, 2025) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners initiates their coverage...
Via Newsfile · September 8, 2025
OS Therapies to Participate in Upcoming Investor Conferences in September 2025
New York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...
Via Newsfile · September 3, 2025
OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting
Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food &...
Via Newsfile · September 2, 2025
OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing
All remaining holders of outstanding warrants with $1.12 per share exercise price have participated, raising $3.7 million in gross proceeds...
Via Newsfile · September 2, 2025
OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025
New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...
Via Newsfile · August 27, 2025
OS Therapies Terminates Equity Line of Credit
New York, New York--(Newsfile Corp. - August 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...
Via Newsfile · August 25, 2025
Os Therapies Posts Wider Loss in Q2fool.com
Via The Motley Fool · August 19, 2025
OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
U.S. FDA ("FDA") confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) FDA issues OST-HER2 BLA number in...
Via Newsfile · August 19, 2025
OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025
New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the...
Via Newsfile · August 14, 2025
OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
66.6% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p = 0.0046)FDA...
Via Newsfile · August 7, 2025
OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
MHRA seeks to harmonize UK & US regulatory review via Project OrbisEMA Rapporteur Scientific Advice Meeting scheduled for October 2025New...
Via Newsfile · August 7, 2025
OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer
Cash runway extended through 2026, beyond September 30, 2026 sunset date for rare pediatric priority review voucher (PRV) program Additional...
Via Newsfile · July 14, 2025
OS Therapies Provides Clinical & Global Regulatory Updates
End of Phase 2 Meeting with FDA scheduled for August 27, 2025 to review OST-HER2 recurrent, pulmonary metastatic osteosarcoma programScientific...
Via Newsfile · July 10, 2025